Most Read Articles
4 days ago
Prenatal and postpartum vitamin D supplementation does not appear to improve foetal or infant growth, a study reports.
6 days ago
Excessive daytime sleepiness appears to increase the long-term risk of amyloid β (Aβ) deposition, a recent study has shown.
6 days ago
Substituting diets high in carbohydrates with those high in monounsaturated fatty acids in the context of low saturated fatty acids do not appear to yield favourable effects on blood pressure, according to a meta-analysis.
12 Sep 2018
Among obese and overweight adults with type 2 diabetes mellitus, women appear to be less likely than men to develop mild cognitive impairment, independent of traditional risk factors, a recent study has shown.

Rituximab may induce remission, allow glucocorticoid tapering in IgAV

06 Dec 2017

Rituximab appears to be safe and effective in the treatment of patients with adult-onset IgA vasculitis (IgAV), inducing disease remission and allowing glucocorticoid tapering, according to a study.

The multicentre, observational study included 22 patients with adult-onset IgAV (formerly Henoch-Schönlein purpura) who had received rituximab for either refractory/relapsing disease or due to contraindications to conventional glucocorticoid/immunosuppressive therapy. The median follow-up was 24 months.

Researchers estimated the rates of remission (defined on the basis of the Birmingham Vasculitis Activity Score, BVAS) and relapse, as well as the variations over time in estimated glomerular filtration rate (eGFR), proteinuria, C-reactive protein levels, BVAS and prednisone dose.

Rituximab was given to 16 patients as add-on therapy and to six as monotherapy. Overall, 20 (90.9 percent) achieved remission and seven (35 percent) subsequently relapsed. Rituximab treatment led to a significant reduction in 24 hour-proteinuria (p<0.0001), C-reactive protein (p=0.0005), BVAS (p<0.0001) and prednisone dose (p<0.0001). Moreover, eGFR remained stable.

In terms of safety, treatment was well tolerated. There was one patient who died after 60 months of follow-up.

Researchers noted that while the use of rituximab in IgAV may potentially reduce the proliferation of IgA-producing plasma cells or deplete tissue-infiltrating B-cells, “its therapeutic efficacy most likely results from the impairment of other B-cell functions such as antigen-presentation and T-cell costimulation, as already postulated in ANCA-associated vasculitis and other autoimmune conditions.” [Nephrol Dial Transplant 2013;29:1151–59]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
Prenatal and postpartum vitamin D supplementation does not appear to improve foetal or infant growth, a study reports.
6 days ago
Excessive daytime sleepiness appears to increase the long-term risk of amyloid β (Aβ) deposition, a recent study has shown.
6 days ago
Substituting diets high in carbohydrates with those high in monounsaturated fatty acids in the context of low saturated fatty acids do not appear to yield favourable effects on blood pressure, according to a meta-analysis.
12 Sep 2018
Among obese and overweight adults with type 2 diabetes mellitus, women appear to be less likely than men to develop mild cognitive impairment, independent of traditional risk factors, a recent study has shown.